Friday 19 Apr 2024
By
main news image

KUALA LUMPUR (Nov 26): CIMB Research has upgraded Hovid Bhd to Hodl (from Reduce) at 38 sen with an unchanged target price of 41 sen and said Hovid’s 1QFY6/15 core net profit was broadly in line, making up 27% of house and consensus full-year forecasts.

In a note Nov 25, the research house said Hovid’s sales and profit margin improved marginally due to higher selling prices and a favourable foreign exchange rate.

It said that as expected, no dividend was declared.

“We trim our FY15-17 EPS by 1-2% after updating our financial model with the latest numbers from its annual report.

“We keep our SOP-based target price at 41 sen, but upgrade it to Hold from Reduce as its share price has corrected by 18% since we downgraded it to Reduce in Aug 14.

“We prefer Pharmaniaga for its higher upside,” it said.

      Print
      Text Size
      Share